See more : TomaGold Corporation (TOGOF) Income Statement Analysis – Financial Results
Complete financial analysis of ShockWave Medical, Inc. (SWAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShockWave Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bukwang Pharmaceutical Co., Ltd. (003000.KS) Income Statement Analysis – Financial Results
- Frontera Group, Inc. (FRTG) Income Statement Analysis – Financial Results
- BLGI, Inc. (BLGI) Income Statement Analysis – Financial Results
- NickelSearch Limited (NIS.AX) Income Statement Analysis – Financial Results
- Hocking Valley Bancshares, Inc. (HCKG) Income Statement Analysis – Financial Results
ShockWave Medical, Inc. (SWAV)
About ShockWave Medical, Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 730.23M | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M | 1.72M |
| Cost of Revenue | 95.39M | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M | 2.84M |
| Gross Profit | 634.84M | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M | -1.12M |
| Gross Profit Ratio | 86.94% | 86.73% | 82.53% | 69.03% | 60.03% | 40.88% | -64.98% |
| Research & Development | 145.65M | 81.68M | 50.54M | 36.93M | 32.85M | 22.70M | 17.96M |
| General & Administrative | 95.27M | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M | 5.42M |
| Selling & Marketing | 234.84M | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M | 6.36M |
| SG&A | 323.20M | 218.92M | 146.04M | 75.54M | 44.75M | 23.52M | 11.79M |
| Other Expenses | 23.96M | 1.06M | -582.00K | 1.26M | 2.35M | 589.00K | 366.00K |
| Operating Expenses | 468.85M | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M | 29.75M |
| Cost & Expenses | 564.24M | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M | 32.58M |
| Interest Income | 0.00 | 1.89M | 1.10M | 1.21M | 944.00K | 0.00 | 0.00 |
| Interest Expense | 6.20M | 1.89M | 1.10M | 1.21M | 944.00K | 401.00K | 58.00K |
| Depreciation & Amortization | 10.36M | -1.42M | -6.87M | 1.26M | 2.35M | 700.00K | 468.00K |
| EBITDA | 176.35M | 127.57M | -871.00K | -62.32M | -49.56M | -39.91M | -30.03M |
| EBITDA Ratio | 24.15% | 25.06% | -3.26% | -95.01% | -115.30% | -325.46% | -1,747.00% |
| Operating Income | 165.99M | 124.13M | -871.00K | -65.66M | -51.84M | -41.20M | -30.87M |
| Operating Income Ratio | 22.73% | 25.35% | -0.37% | -96.86% | -120.76% | -335.97% | -1,795.52% |
| Total Other Income/Expenses | 8.29M | -3.31M | -7.96M | 44.00K | 792.00K | 136.00K | 276.00K |
| Income Before Tax | 174.28M | 120.83M | -8.84M | -65.62M | -51.05M | -41.06M | -30.59M |
| Income Before Tax Ratio | 23.87% | 24.67% | -3.73% | -96.80% | -118.92% | -334.86% | -1,779.46% |
| Income Tax Expense | 27.00M | -95.17M | 301.00K | 80.00K | 62.00K | 38.00K | 26.00K |
| Net Income | 147.28M | 216.00M | -9.14M | -65.70M | -51.11M | -41.10M | -30.62M |
| Net Income Ratio | 20.17% | 44.10% | -3.85% | -96.92% | -119.06% | -335.17% | -1,780.98% |
| EPS | 4.01 | 6.02 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| EPS Diluted | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| Weighted Avg Shares Out | 36.71M | 35.90M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
| Weighted Avg Shares Out (Dil) | 38.21M | 37.88M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd...
Shockwave Medical: Timing The Waves Of Opportunity
Shockwave Medical is a med-tech company that utilizes Intravascular Lithotripsy technology to treat cardiovascular diseases. The company has a significant market presence and stands to capture a significant share of the expanding global cardiovascular intervention market. Shockwave has impressive financial...
Shockwave Medical: Optimal 2024 Setup For Gains
Shockwave Medical is a pioneer in intravascular lithotripsy and has recently experienced a reset valuation due to temporary factors. The company has shown strong revenue growth in 2023, but is facing challenges in its current peripheral business and uncertainty in...
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference
SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper...
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical trials, as companies with early stage drugs are too...
New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men
One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes
A Bull Market Might Be Coming, but These 2 Stocks Aren't Along for the Ride Just Yet
Stock markets were broadly higher on Tuesday. However, Shockwave Medical shares fell despite strong results from the medical device maker in the third quarter of 2023.
Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical, Inc. (SWAV) Q3 2023 Earnings Call Transcript
Shockwave Medical, Inc. (NASDAQ:SWAV ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug Godshall - President and Chief Executive Officer Isaac Zacharias - President and Chief Commercial...
Source: https://incomestatements.info
Category: Stock Reports